natgillin/translations-raw huggingface dataset:
Hvis Deres læge beslutter at ophøre med at give et af indholdsstofferne i Eviplera eller ændre Evipleras dosis, kan De få emtricitabin, rilpivirin og/eller tenofovirdisoproxil hver for sig eller sammen med anden medicin til behandling af hiv-infektion. 
If your doctor decides to stop one of the components of Eviplera or change the dose of Eviplera, you may be given emtricitabine, rilpivirine and/or tenofovir disoproxil separately or with other medicines for the treatment of HIV infection.
Der er rapporteret om sjældne tilfælde af betændelse i bygspytkirtlen og laktatacidose (overskud af mælkesyre i blodet), der somme tider medførte dødsfald, når medicin, der indeholder tenofovirdisoproxil og didanosin, blev indtaget samtidigt. 
Inflammation of the pancreas and lactic acidosis (excess lactic acid in the blood), which sometimes caused death, have been reported rarely when medicines containing tenofovir disoproxil and didanosine were taken together.
Amning skal ophøre under behandling med Eviplera. 
Breast-feeding should be discontinued during treatment with Eviplera.
• Smerter i abdomen (maven), forårsaget af betændelse i bugspytkirtlen 
• Pain in the abdomen (tummy) caused by inflammation of the pancreas
Levertoksicitet forbundet med leverenzyminduktion blev observeret hos gnavere. 
Liver toxicity associated with liver enzyme induction was observed in rodents.
De må ikke amme, mens De er i behandling med Eviplera: 
Do not breast-feed during treatment with Eviplera:
depression2, nedtrykthed2, søvnforstyrrelser2, unormale drømme1, 2 
depression2, depressed mood2, sleep disorders2, abnormal dreams1, 2 Nervous system disorders
Hyppighedskategorien blev estimeret ud fra en statistisk beregning baseret på det totale antal patienter eksponeret for tenofovirdisoproxil i randomiserede, kontrollerede kliniske studier og i programmet for forlænget adgang (n = 7.319). 
The frequency category was estimated from a statistical calculation based on the total number of patients exposed to tenofovir disoproxil in randomised controlled clinical studies and the expanded access program (n = 7,319).
Rilpivirin hæmmer MATE-2K-transportøren in vitro med en IC50 på < 2,7 nM. 
Rilpivirine is an in vitro inhibitor of the transporter MATE-2K with an IC50 of < 2.7 nM.
Virkningen og sikkerheden af skift fra en ritonavir-boosted PI i kombination med to NRTI'er til Eviplera STR blev evalueret i et randomiseret open-label studie hos virologisk supprimerede hiv 1-inficerede voksne. 
The efficacy and safety of switching from a ritonavir-boosted PI in combination with two NRTIs to Eviplera STR was evaluated in a randomised, open-label study in virologically suppressed HIV-1 infected adults.
• antimykobakterielle midler som rifampicin, rifapentin 
• the antimycobacterials rifampicin, rifapentine
Hver filmovertrukket tablet indeholder 277 mg lactosemonohydrat og 4 mikrogram Sunset yellow FCF aluminium lak (E110). 
Each film-coated tablet contains 277 mg lactose monohydrate and 4 micrograms sunset yellow aluminium lake (E110).
Som for andre antiretrovirale lægemidler skal resistenstest og/eller historiske resistensdata være vejledende for anvendelsen af Eviplera (se pkt. 
As with other antiretroviral medicinal products, resistance testing and/or historical resistance data should guide the use of Eviplera (see section 4.4).
• Lavt antal blodplader (en type blodceller, der er involveret i blodets størkning) 
• Low platelet count (a type of blood cell involved in clotting blood)
• Nyrebetændelse, udskillelse af store mængder urin og en fornemmelse af at være tørstig 
• Inflammation of the kidney, passing a lot of urine and feeling thirsty
Hos virologisk supprimerede patienter, som skiftede til Eviplera, var de hyppigst indberettede bivirkninger, som blev anset for at have en mulig eller sandsynlig forbindelse til Eviplera, træthed (3 %), diarré (3 %), kvalme (2 %) og insomni (2 %) (data fra uge 48 fra fase III-studiet GS-US-264-0106). 
In virologically suppressed patients switching to Eviplera, the most frequently reported adverse reactions considered possibly or probably related to Eviplera were fatigue (3%), diarrhoea (3%), nausea (2%) and insomnia (2%) (48 week data from the Phase III study GS-US-264-0106).
Dyreforsøg indikerer hverken direkte eller indirekte skadelige virkninger hvad angår reproduktionstoksicitet (se pkt. 
Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity (see section 5.3) with the components of Eviplera.
Der var 7/317 patienter (2 %) i Eviplera-armen og 6/152 patienter (4 %) i armen med sent skift, som seponerede studielægemidlet permanent pga. en bivirkning opstået under behandlingen (treatmentemergent adverse event (TEAE)). 
There were 7/317 patients (2%) in the Eviplera arm and 6/152 patients (4%) in the Delayed Switch arm who permanently discontinued study drug due to a treatment-emergent adverse event (TEAE).
Hyppighedskategorien blev estimeret ud fra en statistisk beregning baseret på det totale antal patienter eksponeret for Eviplera og alle dets komponenter i randomiserede, kontrollerede kliniske studier (n = 1.261). 
The frequency category was estimated from a statistical calculation based on the total number of patients exposed to Eviplera or all of its components in randomised controlled clinical studies (n = 1,261).
Vira, der indeholder substitutioner, der giver reduceret følsomhed for stavudin og zidovudin (thymidin-analog-associerede mutationer-TAMs; M41L, D67N, K70R, L210W, T215Y/F, K219Q/E) eller didanosin (L74V) vedblev med at være følsomme for emtricitabin. 
Viruses harbouring substitutions conferring reduced susceptibility to stavudine and zidovudine-thymidine analogue-associated mutations-TAMs (M41L, D67N, K70R, L210W, T215Y/F, K219Q/E), or didanosine (L74V) remained sensitive to emtricitabine.
En reduceret dosis på 250 mg didanosin administreret samtidig med tenofovirdisoproxilbehandling er blevet forbundet med store hyppigheder af virologisk svigt for flere testede kombinationer til behandling af hiv 1-infektion. 
A decreased dosage of 250 mg didanosine co-administered with tenofovir disoproxil therapy has been associated with reports of high rates of virological failure within several tested combinations for the treatment of HIV-1 infection.
Hos patienter med nyresygdom i slutstadiet (End Stage Renal Disease, ESRD), som havde behov for hæmodialyse, steg lægemiddelkoncentrationen betragteligt imellem dialyserne over et tidsrum på 72 timer til 53 µg•t/ml (19 %) med emtricitabin og over 48 timer til 42.857 ng•t/ml (29 %) med tenofovir. 
In patients with end-stage renal disease (ESRD) requiring haemodialysis, between dialysis drug exposures substantially increased over 72 hours to 53 µg•h/mL (19%) of emtricitabine, and over 48 hours to 42,857 ng•h/mL (29%) of tenofovir.
Virologisk supprimerede hiv 1-inficerede patienter 
Virologically suppressed HIV-1 infected patients
Eviplera-tabletter skal tages oralt én gang dagligt sammen med mad (se pkt. 
Eviplera must be taken orally, once daily with food (see section 5.2).
Køn Mand Kvinde Etnisk oprindelse Hvid Sort/afrikansk amerikaner Asiatisk Andet Ikke tilladt at spørge om ifølge lokale krav Baseline sygdomskarakteristika Median baseline plasma hiv 1-rna (interval) log10 kopier/ml Median baseline CD4+ celletal (interval), × 106 celler/l 
Sex Male Female Ethnicity White Black/African American Asian Other Not allowed to ask per local regulations Baseline disease characteristics Median baseline plasma HIV-1 RNA (range), log10 copies/mL Median baseline CD4+ cell count (range), x 106 cells/L Percentage of patients with HBV/HCV co-infection
Croscarmellosenatrium Lactosemonohydrat Magnesiumstearat Mikrokrystallinsk cellulose Polysorbat 20 
Croscarmellose sodium Lactose monohydrate Magnesium stearate Microcrystalline cellulose Polysorbate 20
Hvis samtidig anvendelse af Eviplera og nefrotoksiske stoffer ikke kan undgås, skal nyrefunktionen overvåges ugentligt (se pkt. 
If concomitant use of Eviplera and nephrotoxic agents is unavoidable, renal function must be monitored weekly (see sections 4.5 and 4.8).
Ved administration af emtricitabin (en af komponenterne i Eviplera) til pædiatriske patienter, blev de følgende bivirkninger observeret hyppigere ud over de bivirkninger, der blev indrapporteret for voksne: anæmi var almindelig (9,5 %) og misfarvning af huden (øget pigmentering) var meget almindelig (31,8 %) hos pædiatriske patienter (se pkt. 
When emtricitabine (one of the components of Eviplera) was administered to paediatric patients, the following adverse reactions were observed more frequently in addition to the adverse reactions reported in adults: anaemia was common (9.5%) and skin discolouration (increased pigmentation) was very common (31.8%) in paediatric patients (see section 4.8, Tabulated summary of adverse reactions).
4.8), og der skal gives støttende standardbehandling efter behov, herunder observation af patientens kliniske status og overvågning af vitale tegn og EKG (QT-interval). 
If overdose occurs the patient must be monitored for evidence of toxicity (see section 4.8), and standard supportive treatment applied as necessary including observation of the clinical status of the patient and monitoring of vital signs and ECG (QT interval).
• Rygsmerter på grund af nyreproblemer, inklusive nyresvigt. 
• Back pain caused by kidney problems, including kidney failure.
Antacida (f.eks. aluminium- eller magnesiumhydroxid, calciumcarbonat) 
Antacids (e.g. aluminium or magnesium hydroxide, calcium carbonate)
Hvis De kaster op mindre end 4 timer efter, De har taget Eviplera, skal De tage en ny tablet sammen med mad. 
If you vomit less than 4 hours after taking Eviplera, take another tablet with food.
Eviplera frarådes, hvis De har moderat til svær nyresygdom. 
Eviplera is not recommended if you have moderate to severe kidney disease.
GLUKOKORTIKOIDER Dexamethason (systemisk, undtagen enkeltdosisbehandling) 
GLUCOCORTICOIDS Dexamethasone (systemic, except for single dose use)
Sikkerhedsdata fra langtidsbrug for emtricitabin- og tenofovirdisoproxil-komponenterne af Eviplera er imidlertid ikke evalueret hos patienter med let nedsat nyrefunktion. 
However, long-term safety data for the emtricitabine and tenofovir disoproxil components of Eviplera have not been evaluated in patients with mild renal impairment.
Af de 469 Eviplera-behandlede patienter [317 patienter, som skiftede til Eviplera ved baseline (Eviplera-arm), og 152 patienter, som skiftede ved uge 24 (arm med sent skift)], blev i alt 7 patienter undersøgt for udvikling af resistens, og der var genotype- og fænotype-data tilgængelige for alle. 
Of the 469 Eviplera-treated patients [317 patients who switched to Eviplera at baseline (Eviplera arm) and 152 patients who switched at week 24 (Delayed Switch arm)], a total of 7 patients were analysed for resistance development and all had genotypic and phenotypic data available.
Det virologiske respons bevaredes generelt under hele studiet: Af de 12 patienter, som gennemførte studiet, havde 10 patienter suppression ved slutningen af studiet. 
The virologic response was generally preserved throughout the study: of the 12 patients that completed the study, 10 patients were suppressed at the end of the study; in the other 2 patients an increase in viral load was observed only postpartum, for at least 1 patient due to suspected suboptimal adherence.
H2-antagonister kan kun tages én gang dagligt, hvis De tager Eviplera. 
H2-antagonists can only be taken once a day if you take Eviplera.
Eviplera indeholder Sunset yellow FCF aluminium lak, som også kaldes „E110”, der kan medføre allergiske reaktioner. 
Eviplera contains sunset yellow aluminium lake also called “E110” which may cause allergic reactions.
Desuden skal nyrefunktionen (CrCl og serumphosphat) monitoreres efter to til fire ugers behandling, efter tre måneders behandling og derefter hver tredje til sjette måned hos patienter uden renale risikofaktorer. 
It is recommended that CrCl is calculated in all patients prior to initiating therapy with Eviplera and renal function (CrCl and serum phosphate) is also monitored after two to four weeks of treatment, after three months of treatment and every three to six months thereafter in patients without renal risk factors.
forhøjet amylase, herunder forhøjet pancreasamylase1, forhøjet serumlipase1, 2, abdominalsmerter1, 2, 3, mavebesvær2, abdominal distension3, dyspepsi1, flatulens3, mundtørhed2 
elevated amylase including elevated pancreatic amylase1, elevated serum lipase1, 2, abdominal pain1, 2, 3, abdominal discomfort2, abdominal distension3, dyspepsia1, flatulence3, dry mouth2
I fase III-studierne (C209 og C215) er lavere eksponering for rilpivirin, som ligner den der ses under graviditet, blevet associeret med øget risiko for virologisk svigt, hvorfor virusbelastningen bør monitoreres tæt (se pkt. 
In the Phase III studies (C209 and C215), lower rilpivirine exposure, similar to that seen during pregnancy, has been associated with an increased risk of virological failure, therefore viral load should be monitored closely (see sections 4.6, 5.1 and 5.2).
94 % (46/49) af patienterne supprimerede, og hos 4 % (2/49) var der virologisk svigt (hiv 1-rna ≥ 50 kopier/ml). 
At week 48, 94% (46/49) of patients remained suppressed, and 4% (2/49) were considered virologic failures (HIV-1 RNA ≥ 50 copies/mL).
Hiv 1, der indeholder K103Nsubstitutionen eller andre substitutioner forbundet med resistens over for rilpivirin og andre NNRTI'er var følsomme for emtricitabin. 
HIV-1 containing the K103N substitution or other substitutions associated with resistance to rilpivirine and other NNRTIs was susceptible to emtricitabine.
Itraconazol2 
Itraconazole2
• antikonvulsiva som carbamazepin, oxcarbazepin, phenobarbital, phenytoin 
• the anticonvulsants carbamazepine, oxcarbazepine, phenobarbital, phenytoin
Rilpivirin ved den anbefalede dosis på 25 mg én gang dagligt er ikke forbundet med en klinisk relevant virkning på QTc. 
Rilpivirine at the recommended dose of 25 mg once daily is not associated with a clinically relevant effect on QTc.
Den antivirale aktivitet af emtricitabin mod isolater af hiv 1 fra laboratoriet eller klinikken blev vurderet i lymfoblastoide cellelinjer, MAGI-CCR5-cellelinjen og perifere mononukleære blodceller. 
The antiviral activity of emtricitabine against laboratory and clinical isolates of HIV-1 was assessed in lymphoblastoid cell lines, the MAGI-CCR5 cell line, and peripheral blood mononuclear cells.
Median plasma hiv 1-rna var 5,0 og 5,0 log10 kopier/ml, og median CD4+-tælling var 247 x 106 celler/l og 261 x 106 celler/l for patienter, der var randomiseret til hhv. rilpivirin- og efavirenz-armen. 
Median plasma HIV-1 RNA was 5.0 and 5.0 log10 copies/mL and median CD4+ count was 247 x 106 cells/L and 261 x 106 cells/L for patients randomised to rilpivirine and efavirenz arm, respectively.
Patienterne blev randomiseret i forholdet 2:1 til enten skift til Eviplera ved baseline (Eviplera-arm, n = 317) eller til at forblive på deres baseline antiretrovirale program i 24 uger (SBR-arm, n = 159) inden skift til Eviplera i yderligere 24 uger (arm med sent skift, n = 152). 
Patients were randomised in a 2:1 ratio to either switch to Eviplera at baseline (Eviplera arm, n = 317), or stay on their baseline antiretroviral regimen for 24 weeks (SBR arm, n = 159) before switching to Eviplera for an additional 24 weeks (Delayed Switch arm, n = 152).
Blandt patienter i SBR-armen, som forblev på deres baseline-program i 24 uger og dernæst skiftede til Eviplera, havde 92 % (140/152) hiv 1-rna < 50 kopier/ml efter 24 uger med Eviplera, hvilket var overensstemmende med resultaterne ved uge 24 for patienter, som skiftede til Eviplera ved baseline. 
Among patients in the SBR arm who maintained their baseline regimen for 24 weeks and then switched to Eviplera, 92% (140/152) of patients had HIV-1 RNA < 50 copies/mL after 24 weeks of Eviplera, consistent with the week 24 results for patients who switched to Eviplera at baseline.
Eviplera bør anvendes med forsigtighed hos patienter med moderat nedsat leverfunktion (CPT score B), og frarådes hos patienter med svært nedsat leverfunktion (CPT score C). 
Eviplera should be used with caution in patients with moderate hepatic impairment (CPT Score B) and is not recommended in patients with severe hepatic impairment (CPT Score C).
Mikrokrystallinsk cellulose, lactosemonohydrat, povidon, pregelatineret majsstivelse, polysorbat 20, croscarmellosenatrium og magnesiumstearat. 
Microcrystalline cellulose, lactose monohydrate, povidone, pregelatinised maize starch, polysorbate 20, croscarmellose sodium, and magnesium stearate.
Eviplera frarådes til denne population (se pkt. 
Eviplera is not recommended in this population (see section 4.2).
Ved baseline virusbelastning (kopier/ml) 
By baseline viral load (copies/mL)
Når alle tilgængelige data in vitro og data genereret hos tidligere ubehandlede patienter tages i betragtning, kan følgende resistensassocierede mutationer i hiv 1-RT, når de er til stede ved baseline, påvirke aktiviteten af Eviplera: K65R, K70E, K101E, K101P, E138A, E138G, E138K, E138Q, E138R, V179L, Y181C, Y181I, Y181V, M184I, M184V, Y188L, H221Y, F227C, M230I, M230L og kombinationen af L100I og K103N. 
Considering all of the available in vitro data and data generated in previously untreated patients, the following resistance-associated mutations in HIV-1 RT, when present at baseline, may affect the activity of Eviplera: K65R, K70E, K101E, K101P, E138A, E138G, E138K, E138Q, E138R, V179L, Y181C, Y181I, Y181V, M184I, M184V, Y188L, H221Y, F227C, M230I, M230L and the combination of L100I and K103N.
Hvis en patient glemmer at tage en dosis Eviplera i mindre end 12 timer efter tidspunktet, hvor patienten normalt tager dosen, skal patienten tage Eviplera sammen med mad så snart som muligt og derefter fortsætte med den normale doseringsplan. 
If a patient misses a dose of Eviplera within 12 hours of the time it is usually taken, the patient should take Eviplera with food as soon as possible and resume the normal dosing schedule.
Patienterne skulle være på enten deres første eller andet antiretrovirale program uden virologisk svigt i anamnesen, have en anamnese uden nuværende eller tidligere resistens over for nogen af de tre stoffer i Eviplera og være stabilt supprimerede (hiv 1-rna < 50 kopier/ml) i mindst 6 måneder inden screening. 
Patients had to be on either their first or second antiretroviral regimen with no history of virologic failure, have no current or past history of resistance to any of the three components of Eviplera, and must have been stably suppressed (HIV-1 RNA < 50 copies/mL) for at least 6 months prior to screening.
• Andre allergiske reaktioner som piben i lungerne, hævelser eller følelse af svimmelhed 
• Other allergic reactions, such as wheezing, swelling or feeling light-headed
Median stigning i CD4 fra baseline (x 106 celler/l) 
CD4+ median increase from baseline (x 106 cells/L)
Proteasehæmmere (PI) - boostede (med samtidig administration af lavdosis ritonavir) Atazanavir/Ritonavir/Emtricitabin 
Protease inhibitors (PIs) - boosted (with co-administration of low-dose ritonavir) Atazanavir/Ritonavir/Emtricitabine Interaction not studied.
Der foreslås ingen dosisjustering af Eviplera, men der rådes til forsigtighed hos patienter med moderat nedsat leverfunktion. 
No dose adjustment of Eviplera is suggested but caution is advised in patients with moderate hepatic impairment.
• Medicin mod mavesår, halsbrand eller sure opstød (reflukssygdom), såsom: 
• Medicines for stomach ulcers, heartburn or acid reflux such as:
7 Denne bivirkning blev identificeret under sikkerhedsovervågningen efter markedsføring for Eviplera (kombinationsformulering), men den blev ikke observeret i randomiserede, kontrollerede kliniske studier af Eviplera. 
7 This adverse reaction was identified through post-marketing surveillance for Eviplera (fixed-dose combination) but not observed in randomised controlled clinical studies for Eviplera.
3 Bivirkning identificeret for tenofovirdisoproxil. 
3 Adverse reaction identified for tenofovir disoproxil.
Hypromellose, indigocarmin aluminiumpigment, lactosemonohydrat, polyethylenglycol, rød jernoxid, Sunset yellow FCF aluminium lak (E110), titandioxid og triacetin. 
Hypromellose, indigo carmine aluminium lake, lactose monohydrate, polyethylene glycol, red iron oxide, sunset yellow aluminium lake (E110), titanium dioxide, and triacetin.
6 Studiet blev udført med emtricitabin/rilpivirin/tenofoviralafenamid i form af en fastdosis-kombinationstablet. 
6 Study conducted with emtricitabine/rilpivirine/tenofovir alafenamide fixed-dose combination tablet.
• Anden medicin anvendt til hiv-infektion: Non-nukleoside reverse transkriptasehæmmere (NNRTI'er). 
• Other medicines used for HIV infection: Non-nucleoside reverse transcriptase inhibitors (NNRTIs).
• præparater, der indeholder perikon (Hypericum perforatum) (naturmedicin mod depression og angst) 
• products that contain St. John's wort (Hypericum perforatum) (a herbal remedy used for depression and anxiety)
Af de 24 patienter behandlet med Eviplera, som havde præeksisterende NNRTI-associeret K103N-substitution ved baseline i deres hiv 1, bevarede 17 ud af 18 patienter i Eviplera-armen og 5 ud af 6 patienter i SBR-armen virologisk suppression efter skift til Eviplera til og med henholdsvis 48 ugers og 24 ugers behandling. 
Of the 24 patients treated with Eviplera who had the NNRTI-associated K103N substitution pre-existing at baseline in their HIV-1, 17 of 18 patients in the Eviplera arm and 5 of 6 patients in the SBR arm maintained virologic suppression after switching to Eviplera through 48 weeks and 24 weeks of treatment, respectively.
Desuden er en K70E-substitution i hiv 1-RT blevet selekteret af tenofovir, og det forårsager nedsat følsomhed for abacavir, emtricitabin, tenofovir og lamivudin på lavt niveau. 
In addition, a K70E substitution in HIV-1 RT has been selected by tenofovir and results in low-level reduced susceptibility to abacavir, emtricitabine, tenofovir and lamivudine.
Den antivirale aktivitet af tenofovir over for isolater af hiv 1 fra laboratoriet og klinikken blev vurderet i lymfoblastoide cellelinjer, primære monocyt-/makrofage celler og lymfocytter i det perifere blod. 
The antiviral activity of tenofovir against laboratory and clinical isolates of HIV-1 was assessed in lymphoblastoid cell lines, primary monocyte/macrophage cells and peripheral blood lymphocytes.
• Aktive stoffer: emtricitabin, rilpivirin og tenofovirdisoproxil. 
• The active substances are emtricitabine, rilpivirine and tenofovir disoproxil.
1 Dette interaktionsstudie er blevet udført med en dosis af rilpivirinhydrochlorid, der er højere end den anbefalede for at vurdere den maksimale virkning på det samtidigt administrerede lægemiddel. 
1 This interaction study has been performed with a dose higher than the recommended dose for rilpivirine hydrochloride assessing the maximal effect on the co-administered medicinal product.
Ved baseline CD4+-celletal (x 106 celler/l) 
By baseline CD4+ cell count (x 106 cells/L)
En dosisjustering er ikke nødvendig for rilpivirinhydrochlorid hos patienter med let eller moderat nedsat leverfunktion (CPT score A eller B). 
No dose adjustment is required for rilpivirine hydrochloride in patients with mild or moderate hepatic impairment (CPT Score A or B).
Eviplera bør det ikke indgives samtidig med andre lægemidler, som indeholder emtricitabin, tenofovirdisoproxil eller tenofoviralafenamid. 
Eviplera should not be administered concomitantly with other medicinal products containing emtricitabine, tenofovir disoproxil or tenofovir alafenamide.
Hyppigheden af virologisk svigt hos patienter i behandling med emtricitabin/ tenofovirdisoproxil + rilpivirin ved uge 48 og ved uge 96 var hhv. 9,5 % og 11,5 %, mens den var hhv. 4,2 % og 5,1 % i emtricitabin/tenofovirdisoproxil + efavirenz-armen. 
The virologic failure rate in patients treated with emtricitabine/tenofovir disoproxil + rilpivirine at week 48 and week 96 was 9.5% and 11.5% respectively, and 4.2% and 5.1% in the emtricitabine/tenofovir disoproxil + efavirenz arm.
Pakningsstørrelser og yderligere oplysninger Eviplera indeholder: 
Contents of the pack and other information What Eviplera contains